IBM's $40B stock wipeout is built on a misconception: Translating COBOL isn't the same as modernizing it

Investors wiped $40 billion from IBM's market cap after Anthropic released COBOL translation tools. Analysts say the market ...

Has good old COBOL run its course?

COBOL was associated with the Y2K phenomenon at the turn of the century, a software problem arising from the inability of ...

Zeta Global Holdings Corp. (ZETA) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript

Zeta Global Holdings Corp. ( ZETA) Morgan Stanley Technology, Media & Telecom Conference 2026 March 2, 2026 5:35 PM EST ...
The Financial Express

Explainer: How Claude Code threatens to disrupt IBM’s mainframe biz

On3, 2026, Anthropic unveiled Claude Code, an AI tool capable of modernizing decades-old COBOL systems in months rather than years.
The University of Texas at Arlington

The ghosts of open-wheel racing in Arlington

Uncovered Speed: The Legacy of Open-Wheeled Racing in Arlington will run from Feb. 16 through March 16 on the sixth floor of the UTA Central Library. Stop by, explore the exhibit, and discover how ...
Cyber Defense Magazine

The New AI Arsenal: Why LLMs and Transformers Matter for CISOs

As Chief Information Security Officers (CISOs) and security leaders, you are tasked with safeguarding your organization in an ...

When AI learns legacy: How code that rewrites itself is changing IT economics

On 23 Feb 2026, IBM shares dropped 13%, losing nearly $30B, after Anthropic's Claude AI promised faster COBOL modernization, ...
TMCnet

Oracle Red Bull Racing Extends Title Partnership with Oracle in Multi-Year Deal to Power a New Era of Data-Driven Performance

Oracle and Oracle Red Bull Racing today announced a multi-year extension and expansion of their title partnership as the Team prepares for the most significant regulation shift in modern F1 history.

Quants: Unveiling the Market Wizards of Wall Street

Discover how quantitative analysts, or quants, use advanced mathematical models to predict market trends and identify lucrative investment opportunities.
Fierce Biotech

Behind Generate's 'feverish' race to raise $400M IPO while window remains open

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. | Generate:Biomedicines is the latest biotech to benefit from a ...